Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial Patients with chemotherapy-responsive ...
The preferred management of patients with recurrent platinum-sensitive ovarian cancer (PSOC) is platinum-based doublet therapy with selective ...
Morning Overview on MSN
A new drug combo shrank treatment-resistant colon cancer in a large clinical trial
Patients with metastatic colorectal cancer that had stopped responding to at least two prior treatment regimens gained meaningful extra months of life when bevacizumab was added to the chemotherapy ...
Combining bevacizumab (Avastin) with standard chemotherapy eases symptoms in patients with platinum-resistant recurrent ovarian cancer, new results from the AURELIA trial confirm. The study ...
ISELIN, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ...
Bevacizumab addition to chemotherapy showed significant progression-free survival benefits in high-risk epithelial ovarian cancer patients but not in overall survival. The BEV1L study used real-world ...
The use of bevacizumab (Avastin, Genentech/Roche) as a viable treatment for patients with glioblastoma has been hotly debated. But a new study, published in Cancer, now provides the strongest evidence ...
Ovarian cancer comprises a group of different cancers that can form in the ovaries, fallopian tubes, or the peritoneum. For those patients within this population with aggressive disease, continuous ...
For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves ...
The U.S. Bevacizumab Biosimilars Market is projected to grow from USD 0.87 Billion in 2025 to USD 2.41 Billion by 2035, while ...
Corey J. Langer, MD, FACP: Personally, I believe there’s still a role for bevacizumab in select patients despite the astounding survival advantages seen with KEYNOTE-189. There are patients who aren’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results